CD90-MVP

CD90-MVP is a novel gene delivery platform consisting of multiplexed virus-like particles (MVPs) engineered to target CD90 (Thy-1) on hematopoietic stem cells (HSCs). Developed by researchers at the Fred Hutchinson Cancer Center, these particles are cocal-pseudotyped and functionalized with a second-generation anti-CD90 single-chain variable fragment (scFv) for high-specificity targeting. The platform enables in vivo transduction and multiplex gene editing (e.g., using Cas9 protein for HBG locus editing) of long-term engrafting HSCs. This technology aims to bypass the need for ex vivo manipulation and toxic conditioning regimens in HSC gene therapy for disorders like sickle cell disease. Additionally, it can be used in conjunction with CD90 ablation or epitope editing to protect healthy HSCs from CD90-targeted cancer immunotherapies such as CAR-T cells or antibody-drug conjugates.

Other names

CD90-targeted multiplexed virus-like particlesCD-90-targeted multiplexed virus-like particlesCD 90-targeted multiplexed virus-like particlesCD90-targeted MVPsCD-90-targeted MVPsCD 90-targeted MVPs